New Therapeutics for Hepatitis B: The Road to Cure

被引：53

作者：

Naggie, Susanna ^{[1
,2
]}

Lok, Anna S. ^{[3
]}

机构：

[1] Duke Univ, Sch Med, Dept Med, Div Infect Dis, Durham, NC 27701 USA

[2] Duke Clin Res Inst, Durham, NC 27701 USA

[3] Univ Michigan, Sch Med, Dept Internal Med Gastroenterol & Hepatol, Ann Arbor, MI 48109 USA

来源：

ANNUAL REVIEW OF MEDICINE, VOL 72, 2021 | 2021年 / 72卷

关键词：

functional cure; chronic viral hepatitis; HBV surface antigen; curative therapy; targeted antivirals; PEGYLATED INTERFERON ALPHA-2A; CORE-RELATED ANTIGEN; SURFACE-ANTIGEN; HEPATOCELLULAR-CARCINOMA; TENOFOVIR DISOPROXIL; HBSAG SEROCLEARANCE; VIRUS-INFECTION; HBV INFECTION; OPEN-LABEL; REP; 2139;

D O I：

10.1146/annurev-med-080119-103356

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Chronic hepatitis B virus (HBV) infection impacts an estimated 257-291 million people globally. The current approach to treatment for chronic HBV infection is complex, reflecting a risk:benefit approach driven by the lack of an effective curative regimen. This complexity and the lack of a durable treatment response, necessitating indefinite treatment in the majority of cases, have resulted in low uptake of testing and treatment, particularly in regions where comprehensive primary care is lacking and access to affordable testing and treatment is limited. Multiple targeted therapies are now in early human study with the primary goal to achieve persistent HBV DNA and hepatitis B surface antigen suppression after a finite course of treatment, which is referred to as functional cure. This article summarizes the current therapies for HBV infection and discusses the limitations of these therapies, novel approaches to HBV cure, and therapeutic endpoints of clinical trials aimed to cure hepatitis B.

引用

页码：93 / 105

页数：13

共 54 条

[1] Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance [J].

Ahn, SH ;

Park, YN ;

Park, JY ;

Chang, HY ;

Lee, JM ;

Shin, JE ;

Han, KH ;

Park, C ;

Moon, YM ;

Chon, CY .

JOURNAL OF HEPATOLOGY, 2005, 42 (02) :188-194

[2] Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naive to Nucleos(t)ide Therapy [J].

Bazinet, Michel ;

Pantea, Victor ;

Placinta, Gheorghe ;

Moscalu, Iurie ;

Cebotarescu, Valentin ;

Cojuhari, Lilia ;

Jimbei, Pavlina ;

Iarovoi, Liviu ;

Smesnoi, Valentina ;

Musteata, Tatiana ;

Jucov, Alina ;

Dittmer, Ulf ;

Krawczyk, Adalbert ;

Vaillant, Andrew .

GASTROENTEROLOGY, 2020, 158 (08) :2180-2194

[3] Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial [J].

Bazinet, Michel ;

Pantea, Victor ;

Cebotarescu, Valentin ;

Cojuhari, Lilia ;

Jimbei, Pavlina ;

Albrecht, Jeffrey ;

Schmid, Peter ;

Le Gal, Frederic ;

Gordien, Emmanuel ;

Krawczyk, Adalbert ;

Mijocevic, Hrvoje ;

Karimzadeh, Hadi ;

Roggendorf, Michael ;

Vaillant, Andrew .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (12) :877-889

[4] Restoration of HBV-specific CD8+T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation [J].

Bengsch, Bertram ;

Martin, Bianca ;

Thimme, Robert .

JOURNAL OF HEPATOLOGY, 2014, 61 (06) :1212-1219

[5] Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study [J].

Bogomolov, Pavel ;

Alexandrov, Alexander ;

Voronkova, Natalia ;

Macievich, Maria ;

Kokina, Ksenia ;

Petrachenkova, Maria ;

Lehr, Thorsten ;

Lempp, Florian A. ;

Wedemeyer, Heiner ;

Haag, Mathias ;

Schwab, Matthias ;

Haefeli, Walter E. ;

Blank, Antje ;

Urban, Stephan .

JOURNAL OF HEPATOLOGY, 2016, 65 (03) :490-498

[6] Hepatitis B surface antigen quantification: Why and how to use it in 2011-A core group report [J].

Chan, Henry Lik-Yuen ;

Thompson, Alex ;

Martinot-Peignoux, Michelle ;

Piratvisuth, Teerha ;

Cornberg, Markus ;

Brunetto, Maurizia Rossana ;

Tillmann, Hans L. ;

Kao, Jia-Horng ;

Jia, Ji-Dong ;

Wedemeyer, Heiner ;

Locarnini, Stephen ;

Janssen, Harry L. A. ;

Marcellin, Patrick .

JOURNAL OF HEPATOLOGY, 2011, 55 (05) :1121-1131

[7]

Cornberg M, 2020, HEPATOLOGY, V71, P1070, DOI [10.1002/hep.31030, 10.1016/j.jhep.2019.11.003]

[8] The role of quantitative hepatitis B surface antigen revisited [J].

Cornberg, Markus ;

Wong, Vincent Wai-Sun ;

Locarnini, Stephen ;

Brunetto, Maurizia ;

Janssen, Harry L. A. ;

Chan, Henry Lik-Yuen .

JOURNAL OF HEPATOLOGY, 2017, 66 (02) :398-411

[9] Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial [J].

Dore, Gregory J. ;

Feld, Jordan J. ;

Thompson, Alex ;

Martinello, Marianne ;

Muir, Andrew J. ;

Agarwal, Kosh ;

Mullhaupt, Beat ;

Wedemeyer, Heiner ;

Lacombe, Karine ;

Matthews, Gail V. ;

Schultz, Michael ;

Klein, Marina ;

Hezode, Christophe ;

Mercade, Gerard Estivill ;

Kho, Danny ;

Petoumenos, Kathy ;

Marks, Philippa ;

Tatsch, Fernando ;

Dos Santos, Ana Gabriela Pires ;

Gane, Ed ;

Trinh, Roger ;

Erratt, Amanda ;

Mercade, Gerard Estivill ;

Quiene, Sophie ;

Shaw, Ineke ;

Filep, Ecaterina ;

Martinello, Marianne ;

Petoumenos, Kathy ;

Roberts, Stuart ;

Foster, Graham ;

Curry, Michael ;

Warlow, Jenny ;

Mauss, Stefan ;

Stedman, Catherine ;

Vachon, Marie-Louise ;

Christensen, Stefan ;

Muir, Andrew ;

Schultz, Michael ;

Baker, David ;

Ramji, Alnoor ;

Cornberg, Markus ;

Bloch, Mark ;

Hezode, Christophe ;

Bourliere, Marc ;

Lacombe, Karine ;

Semmo, Nasser ;

Agarwal, Kosh ;

Cannon, Mary ;

Tam, Edward ;

Klein, Marina .

JOURNAL OF HEPATOLOGY, 2020, 72 (03) :431-440

[10] THE USE OF INTERFERON-ALPHA IN VIRUS-INFECTIONS [J].

FINTER, NB ;

CHAPMAN, S ;

DOWD, P ;

JOHNSTON, JM ;

MANNA, V ;

SARANTIS, N ;

SHERON, N ;

SCOTT, G ;

PHUA, S ;

TATUM, PB .

DRUGS, 1991, 42 (05) :749-765

← 1 2 3 4 5 6 →